Monitor the upcoming NDA submission for QTORIN rapamycin in microcystic LMs and the initiation of new clinical trials in 2026, as these will be key catalysts for the stock. The earnings miss may pressure the share price short-term, but the strong cash position reduces near-term dilution risk.
Price Chart
Executive Summary
Palvella Therapeutics reported Q4 2025 financial results with a net loss of $41.7 million ($3.71 per share), missing consensus by 15.4%. However, the company highlighted strong clinical progress, including positive Phase 3 data for QTORIN rapamycin in microcystic lymphatic malformations and a $230 million equity financing, leaving it with $274 million in pro forma cash. The stock may react negatively to the earnings miss but could be supported by the robust pipeline advancement and strengthened balance sheet.
Key Financial Metrics
Key Facts
- Net loss of $41.7 million for 2025, or $3.71 per share, missing consensus of $-0.93 by 15.4%.
- Raised $230 million in an oversubscribed public offering, resulting in $274 million of pro forma cash as of December 31, 2025.
- Reported positive Phase 3 SELVA study results for QTORIN rapamycin in microcystic lymphatic malformations, with NDA submission on track for 2H 2026.
- Initiation of Phase 3 trials for QTORIN rapamycin in cutaneous venous malformations and Phase 2 trials for two other indications are planned for 2026.
- Research and development expenses increased to $22.8 million in 2025 from $8.2 million in 2024.
Financial Impact
Net loss of $41.7 million for 2025, with a $230 million equity raise significantly bolstering the balance sheet to $274 million in pro forma cash.
Risk Factors
- Continued high R&D and G&A expenses could pressure the cash runway despite the recent financing.
- Clinical trial setbacks or regulatory delays could negatively impact the company's valuation.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-133332 |
| Document: pvla-20260331.htm | 0001193125-26-133332 |
| Document: pvla-ex99_2.htm | 0001193125-26-133332 |
| Document: 0001193125-26-133332-index-headers.html | 0001193125-26-133332 |
| Document: 0001193125-26-133332-index.html | 0001193125-26-133332 |
| Document: 0001193125-26-133332.txt | 0001193125-26-133332 |
| 8-K Data (Synthetic) | 0001193125-26-133332 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 4w ago | 144 | $155.47 $132.47 | ▼ −14.79% | ▼ −13.61% | $132.47 (−14.79%) |
Aug 9, 2026 7w ago | Institutional Cluster | $152.22 $157.00 | ▲ +3.14% | ▲ +4.05% | $132.47 (−12.97%) |
Aug 4, 2026 8w ago | 8-K | $151.99 $150.55 | ▼ −0.95% | ▲ +0.29% | $132.47 (−12.84%) |
Jul 30, 2026 9w ago | Press Release | $150.19 $150.33 | ▲ +0.09% | ▼ −3.87% | $132.47 (−11.80%) |
Jul 28, 2026 9w ago | Press Release | $142.84 $148.24 | ▲ +3.78% | ▲ +0.40% | $132.47 (−7.26%) |
Jun 30, 2026 13w ago | 8-K | $152.82 $141.77 | ▼ −7.23% | ▼ −6.20% | $132.47 (−13.32%) |
Jun 22, 2026 14w ago | Press Release | $118.84 $157.24 | ▲ +32.31% | ▲ +32.46% | $132.47 (+11.47%) |
Jun 16, 2026 15w ago | 8-K | $110.12 $149.68 | ▲ +35.92% | ▲ +35.72% | $132.47 (+20.30%) |
Jun 11, 2026 16w ago | Institutional Cluster | $106.38 $151.04 | ▲ +41.98% | ▲ +40.09% | $132.47 (+24.53%) |
May 15, 2026 20w ago | 8-K | $114.24 $116.51 | ▲ +1.99% | ▼ −0.13% | $132.47 (+15.96%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access